Day One Biopharmaceuticals, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:DAWN) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Market Capitalization 1.09 B
Employee 181
Founded 2018
CEO N/A
Website www.dayonebio.com
Headquarter Delaware, United States
FIGI BBG00V1KSN04
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

1.09 B Market capitalization

Price to earnings ratio

-8.96

Price to sales ratio

6.08

Dividends per share

—

Dividend yield %

—

Notizie

Needham riduce il target di prezzo di Day One Biopharmaceuticals per i costi

Needham lowers Day One Biopharmaceuticals price target on costs

H.C. Wainwright riduce il target di Day One Biopharmaceuticals a $22

H.C. Wainwright lowers Day One Biopharmaceuticals price target to $22

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript

Day One Biopharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:DAWN) 2026-02-25

Gli EPS di Day One Biopharmaceuticals hanno mancato le aspettative per 0,02$, il fatturato supera le previsioni

Day One Biopharmaceuticals earnings missed by $0.02, revenue topped estimates

Day One Biopharmaceuticals supera le stime sui ricavi

Day One Biopharmaceuticals beats revenue estimates

Day One Biopharmaceuticals: risultati in arrivo dopo l’accordo Mersana

Day one Biopharma CCO sold $67k in DAWN stock